Company intelligence / Profile preview

Cellens

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Preliminary clinical data demonstrate 94% accuracy (91% sensitivity, 82% specificity) for non-invasive detection of bladder cancer recurrence using voided urine samples, with clinical validation at major cancer centers in progress[2][7].

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapyMachine learning-based diagnostics
Industry: Pathology

Partnerships

Bruker BioAFM (strategic collaboration for development and clinical diagnostics)[1]Tufts University (academic and IP partnership)[3]Dana-Farber Cancer Institute (clinical study site)[4]Brigham and Women's Hospital (clinical study site)[4]Tufts Medical Center (clinical study site)[4]

Beyond the preview

Go deeper on Cellens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellens.

Explore the full profile